Your browser is no longer supported. Please, upgrade your browser.
ILMN [NASD]
Illumina, Inc.
IndexS&P 500 P/E66.78 EPS (ttm)6.07 Insider Own0.10% Shs Outstand156.30M Perf Week9.39%
Market Cap62.44B Forward P/E99.15 EPS next Y4.09 Insider Trans-12.06% Shs Float155.65M Perf Month3.42%
Income906.00M PEG23.03 EPS next Q0.48 Inst Own88.10% Short Float1.09% Perf Quarter-1.17%
Sales4.28B P/S14.59 EPS this Y-34.10% Inst Trans0.31% Short Ratio1.75 Perf Half Y-13.75%
Book/sh69.69 P/B5.81 EPS next Y-27.42% ROA9.00% Target Price429.94 Perf Year7.65%
Cash/sh8.21 P/C49.36 EPS next 5Y2.90% ROE14.30% 52W Range341.03 - 555.77 Perf YTD6.49%
Dividend- P/FCF133.14 EPS past 5Y7.40% ROI6.50% 52W High-27.10% Beta0.87
Dividend %- Quick Ratio2.20 Sales past 5Y7.90% Gross Margin69.30% 52W Low18.80% ATR16.02
Employees7800 Current Ratio2.70 Sales Q/Q39.50% Oper. Margin-0.70% RSI (14)57.73 Volatility5.62% 3.74%
OptionableYes Debt/Eq0.16 EPS Q/Q71.30% Profit Margin21.20% Rel Volume1.05 Prev Close399.51
ShortableYes LT Debt/Eq0.16 EarningsNov 04 AMC Payout0.00% Avg Volume973.89K Price405.14
Recom2.80 SMA205.85% SMA506.48% SMA200-4.38% Volume1,019,739 Change1.41%
Jan-11-22Upgrade Barclays Underweight → Equal Weight
Jan-07-22Upgrade BofA Securities Underperform → Neutral
Jan-06-22Resumed Piper Sandler Overweight $450
Jan-06-22Resumed Morgan Stanley Equal-Weight $425
Oct-15-21Resumed Cowen Outperform $550
Aug-19-21Downgrade SVB Leerink Outperform → Mkt Perform $425
Jun-01-21Upgrade Evercore ISI Underperform → In-line $400
Mar-31-21Upgrade Canaccord Genuity Hold → Buy $445
Mar-31-21Downgrade Atlantic Equities Overweight → Neutral $390
Mar-03-21Initiated Barclays Underweight $325
Dec-22-20Upgrade Piper Sandler Neutral → Overweight $340 → $415
Dec-17-20Upgrade BTIG Research Neutral → Buy $410
Oct-13-20Downgrade Guggenheim Buy → Neutral
Sep-30-20Initiated Atlantic Equities Overweight $355
Sep-29-20Downgrade Wolfe Research Outperform → Peer Perform
Sep-22-20Downgrade UBS Buy → Neutral $390 → $285
Sep-22-20Downgrade Stifel Buy → Hold $380 → $280
Sep-21-20Upgrade Guggenheim Neutral → Buy $345
Sep-21-20Downgrade JP Morgan Overweight → Neutral $390 → $280
Sep-09-20Initiated Morgan Stanley Equal-Weight $400
Jan-14-22 08:32AM  
Jan-13-22 12:10PM  
09:00AM  
Jan-12-22 01:00PM  
09:35AM  
09:31AM  
Jan-11-22 06:34PM  
03:30PM  
03:16PM  
01:24PM  
11:55AM  
11:32AM  
02:51AM  
Jan-10-22 04:21PM  
04:19PM  
04:19PM  
04:17PM  
04:15PM  
04:15PM  
08:45AM  
08:15AM  
Jan-07-22 09:30AM  
09:01AM  
Jan-06-22 12:32PM  
Jan-05-22 05:38PM  
04:15PM  
09:02AM  
07:59AM  
Jan-04-22 09:00AM  
Jan-03-22 06:04AM  
Dec-28-21 09:11AM  
Dec-27-21 09:18AM  
Dec-23-21 04:05PM  
Dec-22-21 12:03PM  
Dec-20-21 09:02AM  
07:05AM  
Dec-17-21 09:04AM  
09:02AM  
Dec-16-21 05:38PM  
06:02AM  
05:54AM  
Dec-15-21 01:06PM  
09:06AM  
Dec-14-21 03:21PM  
Dec-10-21 12:01PM  
Dec-09-21 04:00AM  
Dec-08-21 02:38PM  
01:31PM  
10:54AM  
Dec-07-21 04:35PM  
Dec-06-21 07:05AM  
Dec-04-21 08:21AM  
Dec-03-21 01:16PM  
Dec-02-21 11:31AM  
Nov-30-21 12:31PM  
09:41AM  
09:23AM  
Nov-28-21 04:02AM  
Nov-24-21 11:30AM  
Nov-23-21 08:07AM  
07:54AM  
Nov-22-21 05:37PM  
01:16PM  
Nov-17-21 04:05PM  
09:26AM  
Nov-16-21 02:44PM  
01:06PM  
12:16PM  
11:15AM  
Nov-15-21 01:21PM  
Nov-12-21 12:11PM  
Nov-08-21 01:38PM  
Nov-07-21 08:56AM  
Nov-05-21 04:21PM  
02:17PM  
11:39AM  
07:52AM  
Nov-04-21 11:02PM  
05:45PM  
04:05PM  
10:43AM  
08:31AM  
Nov-03-21 04:05PM  
03:25PM  
11:40AM  
08:02AM  
Oct-29-21 01:46PM  
12:04PM  
06:29AM  
06:08AM  
Oct-28-21 02:16PM  
Oct-27-21 08:01AM  
03:05AM  
Oct-26-21 01:33PM  
Oct-22-21 07:08AM  
Oct-21-21 03:31PM  
09:16AM  
Oct-20-21 06:00PM  
Oct-19-21 10:02AM  
09:25AM  
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. It has collaboration agreements with Geneseeq Technology Inc. to develop comprehensive in-vitro diagnostic (IVD) NGS testing kits for cancer; LetsGetChecked to track COVID-19 variants in California; and Merck & Co., Inc. to develop and commercialize tests that identify genetic mutations used in the assessment of homologous recombination deficiency. The company was incorporated in 1998 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
TOUSI SUSAN HSVP, Chief Commercial OfficerJan 12Sale425.00800340,00039,274Jan 13 04:48 PM
TOUSI SUSAN HSVP, Chief Commercial OfficerDec 28Sale387.0610038,70640,074Dec 30 04:10 PM
Dadswell CharlesSVP & General CounselDec 22Sale380.29322122,4533,283Dec 23 05:37 PM
TOUSI SUSAN HSVP, Chief Commercial OfficerDec 08Sale375.0010037,50040,174Dec 09 04:32 PM
Dadswell CharlesSVP, General CounselNov 22Sale377.86314118,6483,605Nov 24 04:16 PM
Aravanis AlexanderSVP, Chief Technology OfficerNov 12Sale386.35361139,4724,127Nov 16 04:52 PM
Febbo Phillip G.SVP Chief Medical OfficerNov 08Sale406.831,000406,8303,015Nov 09 04:59 PM
Aravanis AlexanderSVP, Chief Technology OfficerNov 02Sale412.782,9261,207,8014,679Nov 04 06:11 PM
TOUSI SUSAN HSVP, Chief Commercial OfficerOct 28Sale414.3510041,43541,256Nov 01 04:33 PM
Aravanis AlexanderSVP, Chief Technology OfficerOct 26Sale423.002,9261,237,6987,605Oct 28 05:27 PM
Dadswell CharlesSVP & General CounselOct 22Sale411.00314129,0544,658Oct 26 04:48 PM
Aravanis AlexanderSVP, Chief Technology OfficerOct 19Sale411.822,9261,204,97210,531Oct 21 05:50 PM
Aravanis AlexanderSVP, Chief Technology OfficerOct 12Sale409.212,9261,197,35013,457Oct 14 06:29 PM
TOUSI SUSAN HSVP, Chief Commercial OfficerSep 28Sale418.0410041,80441,356Sep 30 04:04 PM
Dadswell CharlesSVP & General CounselSep 22Sale436.69314137,1214,972Sep 23 04:24 PM
TOUSI SUSAN HSVP, Chief Commercial OfficerAug 30Sale463.50300139,05041,456Sep 01 07:15 PM
Dadswell CharlesSVP & General CounselAug 23Sale489.10314153,5775,286Aug 25 04:40 PM
TOUSI SUSAN HSVP, Chief Commercial OfficerAug 04Sale500.001,000500,00041,756Aug 05 04:22 PM
Hoyt Aimee LSVP, Chief People OfficerAug 04Sale500.00372186,0003,757Sep 08 07:36 PM
TOUSI SUSAN HSVP, Chief Commercial OfficerJul 28Sale486.41300145,92342,743Jul 29 04:34 PM
Dadswell CharlesSVP & General CounselJul 22Sale482.23314151,4205,576Jul 26 04:57 PM
Aravanis AlexanderSVP, Chief Technology OfficerJul 07Sale477.59539257,4214,679Jul 07 06:26 PM
TOUSI SUSAN HSVP, Chief Commercial OfficerJun 28Sale478.95300143,68543,043Jun 30 05:27 PM
Hoyt Aimee LSVP, Chief People OfficerJun 24Sale475.00500237,5004,111Sep 08 07:36 PM
Dadswell CharlesSVP & General CounselJun 22Sale461.01314144,7575,890Jun 24 05:41 PM
Febbo Phillip G.SVP Chief Medical OfficerJun 11Sale447.591,000447,5884,461Jun 14 05:50 PM
DORSA CAROLINEDirectorJun 10Sale450.001,000450,0008,501Jun 14 05:48 PM
Hoyt Aimee LSVP, Chief People OfficerJun 10Sale450.00500225,0004,611Sep 08 07:36 PM
Dadswell CharlesSVP & General CounselMay 24Sale403.04314126,5556,204May 26 04:50 PM
TOUSI SUSAN HSVP, Chief Commercial OfficerMay 20Sale400.00500200,00043,343May 24 04:43 PM
FLATLEY JAY TDirectorMay 18Sale379.534,0001,518,120148,933May 20 04:51 PM
TOUSI SUSAN HSVP Product DevelopmentMay 05Sale381.88300114,56443,843May 06 05:26 PM
FLATLEY JAY TDirectorMay 04Sale384.154,0001,536,600152,933May 06 05:21 PM
Dadswell CharlesSVP & General CounselApr 22Sale402.02314126,2346,518Apr 26 07:52 PM
FLATLEY JAY TDirectorApr 20Sale401.834,0001,607,320156,933Apr 22 05:05 PM
FLATLEY JAY TDirectorApr 06Sale423.444,0001,693,740160,933Apr 07 04:41 PM
TOUSI SUSAN HSVP Product DevelopmentApr 06Sale423.44500211,71844,143Apr 07 04:34 PM
Hoyt Aimee LSVP, Chief People OfficerApr 06Sale424.221,000424,2185,111Sep 08 07:36 PM
TOUSI SUSAN HSVP Product DevelopmentApr 05Sale386.03300115,80944,643Apr 07 04:34 PM
Hoyt Aimee LSVP, Chief People OfficerApr 05Sale386.031,000386,0306,111Sep 08 07:36 PM
Dadswell CharlesSVP & General CounselMar 22Sale416.24314130,6996,832Mar 24 04:41 PM
FLATLEY JAY TDirectorMar 16Sale421.064,0001,684,240164,933Mar 18 07:20 PM
TOUSI SUSAN HSVP Product DevelopmentMar 05Sale402.24800321,79244,943Mar 09 05:29 PM
FLATLEY JAY TDirectorMar 02Sale444.614,0001,778,440168,933Mar 04 05:04 PM
MCGINNIS KAREN KVP, Chief Accounting OfficerFeb 18Sale486.75666324,1761,538Feb 22 05:11 PM
TOUSI SUSAN HSVP Product DevelopmentFeb 17Option Exercise0.006,306048,921Feb 18 04:52 PM
SAMAD SAMSVP and CFOFeb 17Option Exercise0.004,37909,355Feb 18 04:51 PM
RAGUSA ROBERT PSVP, Global Quality & OpsFeb 17Option Exercise0.006,306012,795Feb 18 04:49 PM
MCGINNIS KAREN KVP, Chief Accounting OfficerFeb 17Option Exercise0.0093502,576Feb 18 04:47 PM
Hoyt Aimee LSVP, Chief People OfficerFeb 17Option Exercise0.004,62508,873Feb 18 04:45 PM
Febbo Phillip G.SVP Chief Medical OfficerFeb 17Option Exercise0.003,17307,046Feb 18 04:44 PM
deSouza Francis APresident and CEOFeb 17Option Exercise0.0024,521085,934Feb 18 04:42 PM
Dadswell CharlesSVP & General CounselFeb 17Option Exercise0.003,50308,781Feb 18 04:41 PM
FLATLEY JAY TDirectorFeb 16Sale495.09500247,5433,500Feb 18 07:08 PM
FLATLEY JAY TDirectorFeb 16Sale505.264,0002,021,040172,933Feb 18 07:08 PM
TOUSI SUSAN HSVP Product DevelopmentFeb 05Sale431.90800345,52039,713Feb 09 04:48 PM
Hoyt Aimee LSVP, Chief People OfficerFeb 02Sale444.845725,3562,359Feb 03 05:00 PM
FLATLEY JAY TDirectorFeb 02Sale444.844,0001,779,360176,933Feb 03 04:58 PM
MCGINNIS KAREN KVP, Chief Accounting OfficerFeb 02Sale444.847232,0281,538Feb 03 04:57 PM
deSouza Francis APresident and CEOFeb 01Sale439.783,0001,319,33052,603Feb 03 04:56 PM
TOUSI SUSAN HSVP Product DevelopmentJan 20Sale400.002,5001,000,00040,447Jan 21 04:40 PM
FLATLEY JAY TDirectorJan 19Sale382.484,0001,529,920180,933Jan 21 04:38 PM